{"id":2256,"date":"2026-06-10T15:00:00","date_gmt":"2026-06-10T18:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2256"},"modified":"2026-06-10T15:00:00","modified_gmt":"2026-06-10T18:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-neuro-alta-complexidade-gliomas-meningiomas-tmz-bevacizumab-ttfields-srt","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-neuro-alta-complexidade-gliomas-meningiomas-tmz-bevacizumab-ttfields-srt\/","title":{"rendered":"PGRSS neuro: glioma, mening, TMZ, TTFields"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica neurocirurgia que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica neuro alta complexidade<\/strong> + gliomas glioblastoma GBM IDH-wildtype WHO grade 4 + astrocitoma IDH-mutated grades 2-4 + oligodendroglioma 1p\/19q codeleted<\/strong> + meningioma WHO grade 1-3 + Simpson 1-5<\/strong> + met\u00e1stase cerebral mais comum tumor SNC<\/strong> + TMZ temozolomida Stupp protocol<\/strong> + bevacizumab Avastin recidiva<\/strong> + TTFields Tumor Treating Fields Optune Novocure<\/strong> + SRT\/SRS Gamma Knife+CyberKnife<\/strong> + vorasidenib Voranigo IDH1\/2 INDIGO<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (GBM + astrocitoma + oligodendroglioma + meningioma + ependimoma + meduloblastoma + craniofaringioma + adenoma hip\u00f3fise + met\u00e1stase) + Grupo A4 (linfa cervical raro + bi\u00f3psia estereot\u00e1xica + craniotomia awake mapping) + Grupo C (Iridium-192 brachy raro + I-131 raro + I-125 GliaSite + Cs-131 Isoray + Lutetium-177 PRRT meningioma somatostatin receptor) + Grupo E (perfuro bi\u00f3psia estereot\u00e1xica BrainLab+Stryker Stealth+Medtronic StealthStation + DBS+SEEG eletrodo + EVD external ventricular drain) + Lista C5 (TMZ Temodar Schering 75 mg\/m\u00b2\/d concomitante RT+150-200mg\/m\u00b2 5\/28d adjuvante Stupp + bevacizumab Avastin Genentech anti-VEGF recidiva + lomustina CCNU + carmustina BCNU Gliadel wafer + vorasidenib Voranigo Servier IDH1\/2 INDIGO + ivosidenib Tibsovo IDH1 + dabrafenib+trametinib BRAF V600E pedi\u00e1trico+adulto + larotrectinib Vitrakvi NTRK + selpercatinib Retevmo RET). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + Stupp protocol + TTFields<\/strong> + subdimensionam Lista C5 imuno+targeted<\/strong> + perdem rastreabilidade tumor SNC<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS neuro opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (GBM 50% + astrocitoma 15% + oligodendroglioma 5% + meningioma 35% + outros), A4 (craniotomia awake+mapping iMRI+iCT), C (Lu-177 PRRT meningioma + I-125 GliaSite + Cs-131 Isoray), E (estereotaxia BrainLab+Stealth+iMRI), Lista C5 (Stupp TMZ+RT 60Gy\/30 + bevacizumab + TTFields Optune + vorasidenib Voranigo INDIGO).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica neuro alta complexidade, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos neuro<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS neuro tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 GBM+astro+oligo+mening<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nWHO grade+IDH+1p\/19q<\/td>\n<\/tr>\n
A4 craniotomia awake+iMRI<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nBrainLab+Stealth+iMRI<\/td>\n<\/tr>\n
C Lu-177+I-125+Cs-131<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nPRRT+GliaSite+Isoray<\/td>\n<\/tr>\n
E estereotaxia+DBS+SEEG<\/td>\n0,5-1,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nStealthStation+EVD<\/td>\n<\/tr>\n
Lista C5 TMZ+bev+TTFields<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nStupp+Optune+vorasidenib<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,5-32,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica neuro m\u00e9dia porte.<\/p>\n

A1 GBM + astrocitoma + oligodendroglioma + meningioma + classifica\u00e7\u00e3o WHO 2021: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS neuro \u00e9 A1. Padr\u00e3o setorial inclui (a) GBM glioblastoma WHO 2021 grade 4 IDH-wildtype<\/strong> com astr\u00f3citos+H3K27M+H3G34 + EGFR amplification + TERT promoter + MGMT metila\u00e7\u00e3o progn\u00f3stico+predi\u00e7\u00e3o TMZ + sobrevida 14-18 meses Stupp; (b) astrocitoma IDH-mutated grades 2-4<\/strong> com IDH1-R132H+IDH1-R132C+IDH1-R132G+IDH2-R172 + ATRX perdida + 1p\/19q intacto + sobrevida 5-10y; (c) oligodendroglioma IDH-mutated 1p\/19q codeleted<\/strong> com TERT+CIC+FUBP1 muta\u00e7\u00f5es + responsivo PCV procarbazina+CCNU+vincristina + sobrevida 10-15y; (d) meningioma WHO grade 1-3<\/strong> com 80% G1 benigno + 18% G2 at\u00edpico + 2% G3 anapl\u00e1sico + Simpson 1-5 ressec\u00e7\u00e3o + NF2 muta\u00e7\u00e3o + AKT1+TRAF7+SMO+POLR2A; (e) outros tumores SNC<\/strong> ependimoma SE\/ML\/PF\/SP+meduloblastoma WNT\/SHH\/grupo3\/4+craniofaringioma BRAF-V600E+adenoma hip\u00f3fise+CID C71\/C70\/D32+TNM 8\u00aa SNC.<\/p>\n

Cl\u00ednica com A1 neuro madura garante margem maximal safe resection<\/strong> + previne d\u00e9ficit neurol\u00f3gico<\/strong> + otimiza WHO 2021 + IDH + 1p\/19q + MGMT<\/strong>. Como discutimos no post sobre hospital especializado<\/a>, A1 neuro \u00e9 base.<\/p>\n

A4 craniotomia awake + mapping + iMRI + iCT + 5-ALA fluoresc\u00eancia: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) craniotomia awake<\/strong> com paciente acordado mapping cortical+subcortical + linguagem Wada-test + fun\u00e7\u00e3o sensitivomotora + DCS direct cortical stimulation + Penfield mapping; (b) iMRI Intraoperative MRI<\/strong> com BrainLab Curve + IMRIS Visius + Medtronic StealthMR + Siemens Magnetom Aera + ressec\u00e7\u00e3o m\u00e1xima preservando fun\u00e7\u00e3o; (c) iCT Intraoperative CT<\/strong> com Medtronic O-arm + Siemens Cios + StealthStation S8 + AxiEM electromagnetic + neuronavega\u00e7\u00e3o; (d) 5-ALA 5-aminolevulinic acid Gliolan Photonamic<\/strong> fluoresc\u00eancia fluoresce\u00edna Schaefer + WaveLight Visulas + ressec\u00e7\u00e3o GBM guided + redu\u00e7\u00e3o residual <0,5cm\u00b3; (e) estereotaxia frame Leksell+Cosman+CRW<\/strong> + frameless StealthStation+BrainLab Vector Vision + bi\u00f3psia agulha+craniotomia minimamente invasiva keyhole + DBS deep brain stimulation Medtronic Activa+Boston Sci Vercise+Abbott Infinity.<\/p>\n

Cl\u00ednica com A4 craniotomia+iMRI+5-ALA madura escala maximal safe resection 95% GTR<\/strong> + previne d\u00e9ficit neurol\u00f3gico permanente <5%<\/strong> + otimiza ressec\u00e7\u00e3o GBM EOR Extent of Resection >95%<\/strong>. Conex\u00e3o com adrenal SBRT<\/a>.<\/p>\n

TMZ Stupp + bevacizumab + TTFields Optune + Lu-177 PRRT meningioma + vorasidenib INDIGO: o est\u00e1gio sist\u00eamico+radio+TTFields<\/h2>\n

A terceira camada \u00e9 Stupp+TTFields+vorasidenib. Padr\u00e3o setorial inclui (a) Stupp protocol GBM 1L<\/strong> RT 60 Gy\/30 fra\u00e7\u00f5es + TMZ temozolomida Temodar Schering 75 mg\/m\u00b2\/d concomitante RT + 4 semanas pausa + TMZ adjuvante 150-200 mg\/m\u00b2 D1-5 q28d \u00d7 6-12 ciclos + sobrevida 14,6m vs 12,1m RT only + MGMT methylation predictor; (b) TTFields Optune Novocure<\/strong> com Tumor Treating Fields 200 kHz alternating electric fields + transducer arrays scalp + 18+ horas\/dia + EF-14 trial 1L GBM + sobrevida 20,9m vs 16,0m TMZ only + EF-31 NSCLC; (c) bevacizumab Avastin Genentech anti-VEGF 2L recidiva GBM<\/strong> 10 mg\/kg IV q2w + AVAglio + RTOG 0825 + monoterapia ou + irinotecan\/lomustina + control edema; (d) vorasidenib Voranigo Servier IDH1\/2 dual inhibitor<\/strong> INDIGO trial + 40mg PO QD + grade 2 IDH-mutant glioma residual\/recurrent + PFS 27,7m vs 11,1m placebo HR 0,39; (e) outras mol\u00e9culas<\/strong> lomustina CCNU + carmustina BCNU Gliadel wafer + procarbazina+CCNU+vincristina PCV oligodendroglioma + Lu-177 DOTATATE PRRT meningioma SSTR2+ + ivosidenib Tibsovo IDH1 + dabrafenib+trametinib BRAF V600E + larotrectinib NTRK Lista C5.<\/p>\n

Cl\u00ednica com Stupp+TTFields+vorasidenib madura escala Stupp OS 14,6m + MGMT 21,7m<\/strong> + escala TTFields EF-14 OS 20,9m<\/strong> + escala vorasidenib INDIGO PFS 27,7m<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade neuro<\/h2>\n

Cl\u00ednica neuro s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica neuro A1 + A4 + Stupp.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica neuro 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa neuro + Stupp+TTFields OS 20,9m + vorasidenib INDIGO PFS 27,7m.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica neuro<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 TMZ+bev+vorasidenib+TTFields<\/strong>. Sem segrega\u00e7\u00e3o TMZ Temodar+bevacizumab Avastin+vorasidenib Voranigo+lomustina+carmustina+procarbazina+ivosidenib+dabrafenib+trametinib + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 GBM + astrocitoma + oligodendroglioma + meningioma<\/strong>. Confunde rastreabilidade tumor + impossibilita WHO 2021+IDH+1p\/19q+MGMT + risco indica\u00e7\u00e3o sist\u00eamica inadequada (Stupp vs PCV vs vorasidenib vs Lu-177 PRRT).<\/p>\n

O terceiro \u00e9 a falta de protocolo MGMT methylation pr\u00e9-Stupp<\/strong>. Sem MGMT promoter methylation pyrosequencing + IDH testing + 1p\/19q FISH + ATRX + EGFR amplification = perda predi\u00e7\u00e3o response Stupp + zero precision medicine.<\/p>\n

A regula\u00e7\u00e3o de PGRSS neuro alta complexidade no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer SNC<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS neuro 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 GBM glioblastoma WHO 2021 grade 4 IDH-wildtype+EGFR amplification+TERT promoter+MGMT methylation+astrocitoma IDH-mutated grades 2-4+oligodendroglioma 1p\/19q codeleted+meningioma G1-G3 Simpson 1-5+NF2+AKT1+TRAF7+ependimoma+meduloblastoma WNT\/SHH+craniofaringioma BRAF+adenoma hip\u00f3fise+CID C71\/C70\/D32, A4 craniotomia awake mapping cortical Wada-test+DCS Penfield+iMRI BrainLab Curve+IMRIS Visius+Medtronic StealthMR+iCT O-arm+Siemens Cios+StealthStation S8+5-ALA Gliolan Photonamic fluoresc\u00eancia+estereotaxia Leksell+Cosman+CRW+frameless+DBS Medtronic Activa+Boston Sci Vercise+Abbott Infinity, C Lu-177 DOTATATE PRRT meningioma SSTR2+I-125 GliaSite+Cs-131 Isoray+Iridium-192 brachy raro+CNEN-NN-3.05, E estereotaxia BrainLab+Stryker Stealth+Medtronic StealthStation+DBS+SEEG+EVD external ventricular drain, Lista C5 Stupp protocol RT 60Gy\/30+TMZ Temodar Schering 75 mg\/m\u00b2\/d+150-200 mg\/m\u00b2 adjuvante+TTFields Optune Novocure 200 kHz EF-14 OS 20,9m+bevacizumab Avastin Genentech AVAglio+RTOG 0825+vorasidenib Voranigo Servier IDH1\/2 INDIGO PFS 27,7m+lomustina CCNU+carmustina BCNU Gliadel wafer+PCV procarbazina+CCNU+vincristina+ivosidenib Tibsovo+dabrafenib+trametinib BRAF+larotrectinib NTRK+selpercatinib RET.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS neuro alta complex: glioma + meningioma + TMZ + TTFields. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2255,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3091,3090,3092],"class_list":["post-2256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-glioma","tag-neuro","tag-ttfields"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2256"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2256\/revisions"}],"predecessor-version":[{"id":4351,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2256\/revisions\/4351"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2255"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}